Literature DB >> 27902825

Association Between the Amount of Vaginal Mesh Used With Mesh Erosions and Repeated Surgery After Repairing Pelvic Organ Prolapse and Stress Urinary Incontinence.

Bilal Chughtai1, Matthew D Barber2, Jialin Mao3, James C Forde1, Sharon-Lise T Normand4, Art Sedrakyan3.   

Abstract

Importance: Mesh, a synthetic graft, has been used in pelvic organ prolapse (POP) repair and stress urinary incontinence (SUI) to augment and strengthen weakened tissue. Polypropylene mesh has come under scrutiny by the US Food and Drug Administration. Objective: To examine the rates of mesh complications and invasive reintervention after the placement of vaginal mesh for POP repair or SUI surgery. Design, Setting, and Participants: This investigation was an observational cohort study at inpatient and ambulatory surgery settings in New York State. Participants were women who underwent transvaginal repair for POP or SUI with mesh between January 1, 2008, and December 31, 2012, and were followed up through December 31, 2013. They were divided into the following 4 groups based on the amount of mesh exposure: transvaginal POP repair surgery with mesh and concurrent sling use (vaginal mesh plus sling group), transvaginal POP repair with mesh and no concurrent sling use (vaginal mesh group), transvaginal POP repair without mesh but concurrent sling use for SUI (POP sling group), and sling for SUI alone (SUI sling group). Main Outcomes and Measures: The primary outcome was the occurrence of mesh complications and repeated invasive intervention within 1 year after the initial mesh implantation. A time-to-event analysis was performed to examine the occurrence of mesh erosions and subsequent reintervention. Secondary analyses of an age association (<65 vs ≥65 years) were conducted.
Results: The study identified 41 604 women who underwent 1 of the 4 procedures. The mean (SD) age of women at their initial mesh implantation was 56.2 (13.0) years. The highest risk of erosions was found in the vaginal mesh plus sling group (2.72%; 95% CI, 2.31%-3.21%) and the lowest in the SUI sling group (1.57%; 95% CI, 1.41%-1.74%). The risk of repeated surgery with concomitant erosion diagnosis was also the highest in the vaginal mesh plus sling group (2.13%; 95% CI, 1.76%-2.56%) and the lowest in the SUI sling group (1.16%; 95% CI, 1.03%-1.31%). Conclusions and Relevance: The combined use of POP mesh and SUI mesh sling was associated with the highest erosion and repeated intervention risk, while mesh sling alone had the lowest erosion and repeated intervention risk. There is evidence for a dose-response relationship between the amount of mesh used and subsequent mesh erosions, complications, and invasive repeated intervention.

Entities:  

Mesh:

Year:  2017        PMID: 27902825     DOI: 10.1001/jamasurg.2016.4200

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  11 in total

1.  Autologous transobturator midurethral sling.

Authors:  Alkan Çubuk; Akif Erbin; Metin Savun; Ali Ayrancı; Burak Üçpınar; Fatih Yanaral; Ömer Sarılar; Şeref Basal; Mehmet Fatih Akbulut
Journal:  Turk J Urol       Date:  2018-12-21

Review 2.  Comparison of synthetic mesh erosion and chronic pain rates after surgery for pelvic organ prolapse and stress urinary incontinence: a systematic review.

Authors:  Eoin MacCraith; Eoghan M Cunnane; Michael Joyce; James C Forde; Fergal J O'Brien; Niall F Davis
Journal:  Int Urogynecol J       Date:  2020-11-25       Impact factor: 2.894

3.  Reoperation rates for pelvic organ prolapse repairs with biologic and synthetic grafts in a large population-based cohort.

Authors:  Ericka M Sohlberg; Kai B Dallas; Brannon T Weeks; Christopher S Elliott; Lisa Rogo-Gupta
Journal:  Int Urogynecol J       Date:  2019-07-12       Impact factor: 2.894

4.  Adverse outcomes after minimally invasive surgery for pelvic organ prolapse in women 65 years and older in the United States.

Authors:  C Emi Bretschneider; Charles D Scales; Oyomoare Osazuwa-Peters; David Sheyn; Vivian Sung
Journal:  Int Urogynecol J       Date:  2022-06-04       Impact factor: 1.932

5.  Long-term outcomes of a randomized controlled trial comparing trans-obturator vaginal mesh with native tissue repair in the treatment of anterior vaginal wall prolapse.

Authors:  Lucie Allègre; Geertje Callewaert; Sandrine Alonso; Arnaud Cornille; Hervé Fernandez; Georges Eglin; Renaud de Tayrac
Journal:  Int Urogynecol J       Date:  2019-09-10       Impact factor: 2.894

6.  Long-term outcome of vaginal mesh or native tissue in recurrent prolapse: a randomized controlled trial.

Authors:  Alfredo L Milani; Anne Damoiseaux; Joanna IntHout; Kirsten B Kluivers; Mariella I J Withagen
Journal:  Int Urogynecol J       Date:  2017-11-22       Impact factor: 2.894

7.  Women's experiences of managing digitation: do we ask enough in primary care?

Authors:  Sharon Eustice; Ruth Endacott; Jenny Morris; Rohit Shankar; Bridie Kent
Journal:  JRSM Open       Date:  2018-08-06

Review 8.  The Novel and Minimally Invasive Treatment Modalities for Female Pelvic Floor Muscle Dysfunction; Beyond the Traditional

Authors:  Yiğit Akın; Matthew Young; Muhammad Elmussareh; Nickolaus Charalampogiannis; Ali Serdar Gözen
Journal:  Balkan Med J       Date:  2018-06-28       Impact factor: 2.021

9.  Role of endoscopic management in synthetic sling/mesh erosion following previous incontinence surgery: a systematic review from European Association of Urologists Young Academic Urologists (YAU) and Uro-technology (ESUT) groups.

Authors:  Sulaiman Sadaf Karim; Amelia Pietropaolo; Andreas Skolarikos; Omar Aboumarzouk; Panagiotis Kallidonis; Thomas Tailly; Vincent de Coninck; Etienne Xavier Keller; Bhaskar Kumar Somani
Journal:  Int Urogynecol J       Date:  2019-08-29       Impact factor: 2.894

Review 10.  Long-term active surveillance of implantable medical devices: an analysis of factors determining whether current registries are adequate to expose safety and efficacy problems.

Authors:  Samprit Banerjee; Bruce Campbell; Josh Rising; Allan Coukell; Art Sedrakyan
Journal:  BMJ Surg Interv Health Technol       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.